Table 2 Representative preclinical experiments about immunosuppressive cells
From: Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
Cell | Target | Drug name | Animal model | Combination therapy | Effect on the TME | References |
|---|---|---|---|---|---|---|
MDSC | NAMPT | FK866 and MV87 | Fibrosarcoma mouse model | PD-1 antibody | Decrease MDSCs, increase T cell | [91] |
— | Resveratrol | Lewis lung carcinoma bearing mice | - | Decrease MDSCs, increase T cell | [95] | |
γ-secretase | DAPT | Head and neck squamous cell carcinoma | - | Decrease MDSCs/TAM/Tregs | [118] | |
DCs | CD-11b | ADH-503 | Pancreatic ductal adenocarcinoma | PD-1/41BB antibody | Promote M1 polarization; Increase cDCs/T cell | [103] |
TLR-7 /IL-10 | let7b | Breast cancer | - | Activate TIDCs; Increase secretion of IL-12/IL-10 | [114] | |
CD169 | CD169 antibodies | Melanoma | - | Increase CD8+T cell response | - | |
TANs | SIRPα | KWAR23 | Burkitt’s lymphoma mice model | Anti-CD70 antibody | Enhance neutrophils and macrophages antitumor activity | [109] |
B11 | EFNB2-EphB4 | Pancreatic ductal adenocarcinoma | Radiation | Decrease Tregs, macrophages, and neutrophils | [113] | |
Tregs | IL-23 | Guselkumab | Renal cell carcinoma | - | Decrease Tregs; Decrease secretion of IL-10/TGF-β; Increase cytotoxicity of CD8+T cells | [135] |
TLR1/2 | Pam3CSK4 | B16/F10 melanoma model | CTLA-4 antibody | Increase M1/T cells; Decrease Tregs | [142] | |
CAFs | Bromodoma | JQ1/ricolinostat | Non-small cell lung cancer model | - | Increase T cell, decrease M2 | - |
HSP90 | Octyl gallate | Pancreatic ductal adenocarcinoma | - | Decrease M2 | [146] | |
mPGES-1 | CIII | Neuroblastoma tumor | - | Decrease M2 | [151] |